Dr. Suzanne Dawn Turner
Researcher, Institute of Medical Genetics and Genomics
e‑mail: |
---|
Total number of publications: 34
2024
-
STAT3 couples activated tyrosine kinase signaling to the oncogenic core transcriptional regulatory circuitry of anaplastic large cell lymphoma
CELL REPORTS MEDICINE, year: 2024, volume: 5, edition: 3, DOI
-
Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma
Nature Communications, year: 2024, volume: 15, edition: 1, DOI
2023
-
Biopathology of childhood, adolescent and young adult non-Hodgkin lymphoma
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY, year: 2023, volume: 36, edition: 1, DOI
-
Improving outcomes of childhood and young adult non-Hodgkin lymphoma: 25 years of research and collaboration within the framework of the European Intergroup for Childhood Non-Hodgkin Lymphoma
LANCET HAEMATOLOGY, year: 2023, volume: 10, edition: 3, DOI
-
Patient-derived xenograft models of ALK plus ALCL reveal preclinical promise for therapy with brigatinib
British journal of haematology, year: 2023, volume: 20, edition: 5, DOI
-
STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway
Molecular Cancer, year: 2023, volume: 22, edition: 1, DOI
-
Targeting CCR7-PI3Kγ overcomes resistance to tyrosine kinase inhibitors in ALK-rearranged lymphoma
Science Translational Medicine, year: 2023, volume: 15, edition: 702, DOI
-
The Pioneer platform: A novel approach for selection of selective anti-cancer cytotoxic activity in bacteria through co-culturing with engineered human cells
Plos one, year: 2023, volume: 18, edition: 6, DOI
-
To Waste or Not to Waste: Questioning Potential Health Risks of Micro- and Nanoplastics with a Focus on Their Ingestion and Potential Carcinogenicity
EXPOSURE AND HEALTH, year: 2023, volume: 15, edition: 1, DOI
2022
-
BRG1 and NPM-ALK Are Co-Regulated in Anaplastic Large-Cell Lymphoma; BRG1 Is a Potential Therapeutic Target in ALCL
CANCERS, year: 2022, volume: 14, edition: 1, DOI